針對伴侶動物的醫療用品趨勢：2006年

Abstract

Overview:

The companion animal sector has been the main driver of growth for the global animal health industry since the mid-1990s.This essential report analyses the size and structure of the companion animal market, profiles the companies leading this sector and assesses prospects for future growth.

Examine in detail market share across the sector with detailed information on size of business, contribution to total sales, key products and future prospects for the sector's current market leaders.

Table of Contents

CHAPTER 1 COMPANION ANIMAL HEALTH PROBLEMS

• 1.1 Infectious diseases
  • 1.1.1 Canine infectious diseases
    • 1.1.1.1 Bordetella bronchiseptica
    • 1.1.1.2 Coronavirus
    • 1.1.1.3 Distemper
    • 1.1.1.4 Hepatitis
    • 1.1.1.5 Influenza
    • 1.1.1.6 Kennel cough
    • 1.1.1.7 Leptospirosis
    • 1.1.1.8 Lyme isease
    • 1.1.1.9 Parvovirus
    • 1.1.1.10 Rabies
    • 1.1.1.11 Feline infectious diseases
    • 1.1.1.12 Feline influenza
    • 1.1.1.13 Chlam ydophila
    • 1.1.1.14 Feline infectious peritonitis
    • 1.1.1.15 Feline leukaemia
    • 1.1.1.16 Panleukopenia
    • 1.1.1.17 Feline immunodeficiency virus
  • 1.1.2 Equine infectious diseases
    • 1.1.2.1 African horse sickness
    • 1.1.2.2 Equine encephalom yelitis
    • 1.1.2.3 Equine infectious anaemia
    • 1.1.2.4 Equine influenza
    • 1.1.2.5 Equine protozoal myeloencephalitis
    • 1.1.2.6 Equine viral arteritis
    • 1.1.2.7 Equine viral rhinopneumonitis
    • 1.1.2.8 Strangles
    • 1.1.2.9 Tetanus
    • 1.1.2.10 West Nile virus
• 1.2 Parasitic infections
  • 1.2.1 Endoparasites
    • 1.2.1.1 Gastrointestinal nem atodes
    • 1.2.1.2 Heartworms
    • 1.2.1.3 Horse bots
    • 1.2.1.4 Lungworms
    • 1.2.1.5 Protozoa
    • 1.2.1.6 Tapeworms
  • 1.2.2 Ectoparasites
    • 1.2.2.1 Fleas
    • 1.2.2.2 Ticks
    • 1.2.2.3 Mites
    • 1.2.2.4 Lice
    • 1.2.2.5 Flies
• 1.3 Musculoskeletal problems
  • 1.3.1 Canine osteoarthritis
  • 1.3.2 Equine lameness
• 1.4 Cardiovascular disease
  • 1.4.1 Cong estive heart failure
  • 1.4.2 Deg enerative valve disease
  • 1.4.3 Cardiom yopathy
• 1.5 Cancer
  • 1.5.1 Mast cell tumors

CHAPTER 2 COMPANION ANIMAL PRODUCTS

• 2.1 Introduction
• 2.2 Anti-infectives
  • 2.2.1 Anti-infective product g roups
    • 2.2.1.1 Am inog lycosides
    • 2.2.1.2 Penicillins
    • 2.2.1.3 Macrolides
    • 2.2.1.4 Lincosamides
    • 2.2.1.5 Tetracyclines
    • 2.2.1.6 Chloramphenicol and derivatives
    • 2.2.1.7 Sulfonamides
    • 2.2.1.8 Cephalosporins
    • 2.2.1.9 Fluoroquinolones
  • 2.2.2 Recent developments
    • 2.2.2.1 New antibiotic active ingredients
      • Cefpodoxime
      • Difloxacin
      • I bafloxacin
      • Marbofloxacin
      • Ofloxacin
      • Orbifloxacin
  • 2.2.3 Future developments
  • 2.2.3.1 Anticipated launch activity
• 2.3 Antiparasitics
  • 2.3.1 Endoparasiticides
  • 2.3.1.1 Endoparasiticide product groups
    • I m idazothiazoles
    • Benzim idazoles
    • Tetrahydropyrim idines
    • Macrocyclic lactones
    • Cyclic depsipeptides
    • Others
  • 2.3.1.2 Recent developments
    • Emodepside
    • Generic penetration
    • Parasite vaccines
  • 2.3.1.3 Future prospects
  • 2.3.1.4 Ectoparasiticide product groups
    • Org anophosphates
    • Carbamates
    • Form amidines
    • Pyrethrins and pyrethroids
    • I nsect growth regulators
    • Phenylpyrazoles
    • Neonicotinoids
    • Recent developments
    • Fipronil
    • Imidacloprid
    • Lufenuron
    • Nitenpyram
    • Pyriproxyfen
    • Future prospects
  • 2.3.1.5 Endectocides
    • Selam ectin
    • Quasi-endectocides
    • Future developments
• 2.4 Anti-inflammatories
  • 2.4.1 Anti-inflam m atory product g roups
    • 2.4.1.1 Corticosteroids
    • 2.4.1.2 Non-steroidal anti-inflammatory drugs
      • Established NSAI Dclasses
      • The coxib NSAI Dsubclass
  • 2.4.2 Recent developments
    • 2.4.2.1 Carprofen
    • 2.4.2.2 Deracoxib
    • 2.4.2.3 Etodolac
    • 2.4.2.4 Firocoxib
    • 2.4.2.5 Meloxicam
    • 2.4.2.6 Tepoxalin
  • 2.4.3 Future prospects
• 2.5 Other pharm aceuticals
  • 2.5.1 Cardiovascular drugs
    • 2.5.1.1 ACE inhibitors
      • Enalapril
      • Benazepril
      • Ramipril
      • Imidapril
      • Alacepril
      • Temocapril
    • 2.5.1.2 Other cardiovascular drugs
  • 2.5.2 Behavioral therapies
  • 2.5.3 Gastrointestinal drugs
  • 2.5.4 Others
  • 2.5.5 Future prospects
    • 2.5.5.1 Cardiovasculars
    • 2.5.5.2 Behavioral therapies
    • 2.5.5.3 Gastrointestinal drugs
    • 2.5.5.4 Others
• 2.6 Biologicals
  • 2.6.1 Biolog ical product groups
    • 2.6.1.1 Canine vaccines
    • 2.6.1.2 Feline vaccines
    • 2.6.1.3 Equine vaccines
    • 2.6.1.4 Diag nostics
  • 2.6.2 Recent developments
    • 2.6.2.1 Sm all animal vaccines
    • 2.6.2.2 Equine vaccines
    • 2.6.2.3 Diag nostics
  • 2.6.3 Future prospects

CHAPTER 3 MAJOR NATIONAL MARKETS FOR COMPANION ANIMAL PRODUCTS

• 3.1 Australia
  • 3.1.1 The Australian market for animal health products
  • 3.1.2 The market for companion animal health products
  • 3.1.3 Companion animal market structure
  • 3.1.4 Companion animal market prospects in Australia
• 3.2 Brazil
  • 3.2.1 The Brazilian market for animal health products
  • 3.2.2 The market for companion animal health products
  • 3.2.3 Companion animal market structure
  • 3.2.4 Companion animal market prospects in Brazil
• 3.3 Canada
  • 3.3.1 The Canadian market for animal health products
  • 3.3.2 The market for companion animal products
  • 3.3.3 Structure of the Canadian companion animal market
  • 3.3.4 Companion animal market prospects in Canada
• 3.4 France
  • 3.4.1 The French market for animal health products
  • 3.4.2 The market for companion animal products
  • 3.4.3 Structure of the French companion animal market
    • Antiparasitics
    • Other pharm aceuticals
    • Biologicals
  • 3.4.4 Companion animal market prospects in France
• 3.5 Germ any
  • 3.5.1 The Germ an market for animal health products
  • 3.5.2 The market for companion animal health products
  • 3.5.3 Companion animal market structure
  • 3.5.4 Companion animal market prospects in Germ any
• 3.6 Italy
  • 3.6.1 The Italian market for animal health products
  • 3.6.2 The market for companion animal health products
  • 3.6.3 Companion animal market structure
  • 3.6.4 Companion animal market prospects in Italy
• 3.7 Japan
  • 3.7.1 The Japanese market for animal health products
  • 3.7.2 The market for companion animal health products
  • 3.7.3 Companion animal market structure
  • 3.7.4 Companion animal market prospects in Japan
• 3.8 Spain
  • 3.8.1 The Spanish market for animal health products
  • 3.8.2 The market for companion animal health products
  • 3.8.3 Companion animal market structure
  • 3.8.4 Companion animal market prospects in Spain
• 3.9 United King dom
  • 3.9.1 The UK market for animal health products
  • 3.9.2 The market for companion animal products
  • 3.9.3 Structure of the companion animal products market
    • Antiparasitics
    • Other pharm aceuticals
    • Biologicals
  • 3.9.4 Companion animal market prospects in the UK
• 3.10 United States of Am erica
  • 3.10.1 The US market for animal health products
  • 3.10.2 The market for companion animal products
  • 3.10.3 Companion animal market structure
    • Antiparasitics
    • Other pharm aceuticals
    • Biologicals
  • 3.10.4 Companion animal market prospects in the US
    • New products and patent expiries

CHAPTER 4 THE GLOBAL MARKET FOR COMPANION ANIMAL PRODUCTS

• 4.1 The g lobal market for animal health products
• 4.2 The g lobal market for companion animal health products
• 4.3 Companion animal product sales by reg ion
• 4.4 Major national markets for companion animal products
• 4.5 Market drivers and constraints
  • 4.5.1 Companion animal populations
    • Developed countries
    • Developing countries
  • 4.5.2 Econom ic, social and demographic trends
    • Economic growth
    • Developed countries
    • Developing countries
    • Social and demographic trends
  • 4.5.3 New products and technologies
    • Market impact
  • 4.5.4 Prom otion and marketing techniques
  • 4.5.5 Companion animal health and disease trends
  • 4.5.6 Patent expiries and generic penetration
    • Ivermectin
    • Other recent generic targets
    • Future generic targets
  • 4.5.7 Product safety issues
    • ProHeart 6
    • NSAI Ds
    • Lessons for the industry
  • 4.5.8 Regulatory factors
    • Market impact
  • 4.5.9 Companion animal health insurance
• 4.6 Future growth of the companion animal products market

CHAPTER 5 COMPANY PROFILES

• 5.1 Introduction
• 5.2 Bayer
  • 5.2.1 Company backg round
  • 5.2.2 Companion animal business
  • 5.2.3 Major companion animal products
    • Other antiparasitics
    • Enrofloxacin
  • 5.2.4 Future developments
• 5.3 Fort Dodg e
  • 5.3.1 Company backg round
  • 5.3.2 Companion animal business
  • 5.3.3 Major companion animal products
    • Vaccines
    • Antiparasitics
    • Other pharm aceuticals
  • 5.3.4 Future developments
• 5.4 Idexx
  • 5.4.1 Company background
  • 5.4.2 Companion animal business
  • 5.4.3 Major companion animal products
    • Rapid assays
    • Pharm aceuticals
  • 5.4.4 Future developments
  • 5.5 I ntervet
  • 5.5.1 Company backg round
  • 5.5.2 Companion animal business
  • 5.5.3 Major companion animal products
    • Vaccines
    • Anti-infectives
    • Antiparasitics
    • Other pharm aceuticals
  • 5.5.4 Future developments
• 5.6 Merial
  • 5.6.1 Company backg round
  • 5.6.2 Companion animal business
  • 5.6.3 Major companion animal products
    • Fipronil
    • Ivermectin
    • Other pharm aceuticals
    • Biologicals
  • 5.6.4 Future developments
• 5.7 Novartis
  • 5.7.1 Company backg round
  • 5.7.2 Companion animal business
  • 5.7.3 Major companion animal products
    • Antiparasitics
    • Anti-inflammatories and dermatological treatments
    • Others
  • 5.7.4 Future developments
• 5.8 Pfizer
  • 5.8.1 Company backg round
  • 5.8.2 Companion animal business
  • 5.8.3 Major companion animal products
    • Anti-infectives
    • Antiparasitics
    • Other pharm aceuticals
    • Vaccines
  • 5.8.4 Future developments
• 5.9 Schering -Ploug h
  • 5.9.1 Company backg round
  • 5.9.2 Companion animal business
  • 5.9.3 Major companion animal products
    • Anti-infectives
    • Anti-inflammatories
    • Antiparasitics
    • Vaccines
    • Others
  • 5.9.4 Future developments
• 5.10 Vetoquinol
  • 5.10.1 Company backg round
  • 5.10.2 Companion animal business
  • 5.10.3 Major companion animal products
    • Anti-infectives
    • Other pharmaceuticals
    • Nutraceuticals
  • 5.10.4 Future developments
• 5.11 Virbac
  • 5.11.1 Company backg round
  • 5.11.2 Companion animal business
  • 5.11.3 Major companion animal products
    • Antiparasitics
    • W orm ers
    • I nsecticides
    • Other pharmaceuticals
    • Biologicals
  • 5.11.4 Future developments